Study title: Narimatsu H, Kami M, Kato D, Matsumura T, Murashige N, Kusumi E et al. 2007; Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. Transplant Infectious Disease 2007; 9(1):11-15.Narimatsu H, Kami M, Kato D, Matsumura T, Murashige N, Kusumi E et al. 2007; Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. Transplant Infectious Disease 2007; 9(1):11-15.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: FOSCARNET | |||||
| ATC code: | |||||
| Document link: Narimatsu H et al. 2007.pdf | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | Y | |